Summary: Migraine is a common medical condition with wide variations in prevalence in different countries. According to WHO estimates, 1.16 billion people suffer from migraine, making it the first neurological disease occurring in children and adolescents and the second most common among adults under the age of 60. The aim of the present article was to presence actually opinion about treatment of migraine. Despite advances in understanding the pathophysiology of migraine and despite the advent of triptans, a class of drugs that targets underlying mechanisms implicated in migraine, self-medication with over-the-counter (OTC) drugs remains the most common form of treatment for migraine. The proportion of individuals treating migraine with OTC medication alone remained almost unchanged during last years. The practice guidelines of the Headache Section of the Polish Neurological Society, and the Polish Pain Society as well as European Headache Society and American Headache Society recommend use migraine-specific agents (triptans, monoclonal antibodies and gepants) in patients with moderate or severe migraine, or whose mild-to- -moderate headaches respond poorly to NSAIDs [nonsteroidal anti-inflammatory drugs] or combinations such as aspirin plus acetaminophen plus caffeine. Early prophylactic treatment of migraine new drugs is effective and improve patients quality of life. Failure to use an effective treatment promptly may increase pain, disability, and the impact of the increasing headache frequencies.